Switch View
© Globe Newswire
05.11.2025
ISIN: US91678A1079
Upstream Bio, Inc.
UPB
LISTED
NASDAQ
Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress
News Preview
– Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary endpoints when administered once every 12 weeks –...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab
News Preview
ZUG, Switzerland, November 5, 2025 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the third quarter of 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US30233G2093
EyePoint Pharmaceuticals Inc
EYPT
LISTED
NASDAQ
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments
News Preview
– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 –...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
05.11.2025
ISIN: IL0006290147
Teva Pharmaceutical Industries Ltd
TEVA
LISTED
TLV
Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
News Preview
For an accessible version of this Press Release, please visit www.tevapharm.com...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
05.11.2025
ISIN: US04683R1068
Atea Pharmaceuticals Inc
AVIR
LISTED
NASDAQ
Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
News Preview
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, November 12,...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US03753U1060
Apellis Pharmaceuticals Inc
APLS
LISTED
NASDAQ
Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference
News Preview
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:40 p.m. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US35168W1036
Fractyl Health Inc
GUTS
LISTED
NASDAQ
Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025
News Preview
BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the third quarter 2025 and provide business updates on W...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US4448591028
Humana Inc
HUM
LISTED
NYSE
Humana Reports Third Quarter 2025 Financial Results; Affirms Full Year 2025 Adjusted EPS Guidance
News Preview
Humana Inc. (NYSE: HUM) today reported consolidated pretax results and diluted earnings per share (EPS) for the quarter ended September 30, 2025 (3Q25) versus the quarter ended September 30, 2024 (3Q24) and for the nine months ended September 30, 2025 (YTD 2025) versus the nine months ended September 30, 2024 (YTD 2024) as noted in the tables belo...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: GB00BYMT0J19
LivaNova PLC
LIVN
LISTED
NASDAQ
LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2025 and raised full-year 2025 guidance.
Financial Summary and Highlights(1)
Third-quarter revenue of $357.8 million increased 12.5% on a reported basis, 11.0% on a constant-currency basis, and 12.5% on an o...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US75629V1044
Recursion Pharmaceuticals Inc
RXRX
LISTED
NASDAQ
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
SALT LAKE CITY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its third quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US67577C1053
Ocugen Inc
OCGN
LISTED
NASDAQ
Ocugen Provides Business Update with Third Quarter 2025 Financial Results
News Preview
Conference Call and Webcast Today at 8:30 a.m. ET Conference Call and Webcast Today at 8:30 a.m. ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US34965KAA51
Fortrea Holdings, Inc.
FTRE
LISTED
NASDAQ
Fortrea Reports Third Quarter 2025 Results
News Preview
For the three months ended September 30, 2025, from continuing operations:...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
05.11.2025
ISIN: US75629V1044
Recursion Pharmaceuticals Inc
RXRX
LISTED
NASDAQ
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth
News Preview
Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: KYG7S12M1051
XtalPi Holdings Limited
2228
LISTED
HKSE
XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development
News Preview
SHANGHAI, Nov. 5, 2025 /PRNewswire/ -- Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and Company ("Lilly") to accelerate the discovery and development of b...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: KYG7S12M1051
XtalPi Holdings Limited
2228
LISTED
HKSE
XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development
News Preview
SHANGHAI, Nov. 5, 2025 /PRNewswire/ -- Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and Company ("Lilly") to accelerate the discovery and development of b...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US7504911022
RadNet Inc
RDNT
LISTED
NASDAQ
RadNet Expands Comprehensive Remote Scanning Offering with Acquisition of Alpha RT’s Assets
News Preview
DeepHealth commercializes remote-imaging offering featuring TechLive™ remote scanning and Alpha RT’s MRI staffing services, training and safety software....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: AU000000IMC7
Immuron Limited
IMC
LISTED
ASX
Immuron IMM-529 IND approved by FDA
News Preview
Key Points...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: US6979471090
Palvella Therapeutics Inc
PVLA
LISTED
NASDAQ
Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies
News Preview
DSAP is a premalignant, progressive disease characterized by numerous expanding lesions which significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. patients...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: AU000000TLX2
Telix Pharmaceuticals Ltd
TLX
LISTED
ASX
Telix to Participate in UBS and Jefferies Global Healthcare Conferences
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will participate in the upcoming UBS Global Healthcare Conference in Palm Beach, FL (U.S.) and in the Jefferies Global Healthcare Conference in London (UK)....
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: SE0022419784
Sectra AB
SECT_B
LISTED
STO
Top-rated Canadian healthcare provider adopts Sectra's enterprise imaging as a cloud solution for enhanced patient care
News Preview
LINKÖPING, Sweden and MISSISSAUGA, ON, Nov. 5, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) is implementing its enterprise imaging as a fully managed cloud solution at Southlake Health in Canada. This will streamline workflows and facilitate collaboration wi...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US40131M1099
Guardant Health Inc
GH
LISTED
NASDAQ
Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering
News Preview
Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its upsized offering of $350.0 million aggregate principal amount of 0% convertible senior notes due 2033 (the “notes”) in a private offering (the “convertible notes offering”) to persons reasonably believed to be qualified...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US40131M1099
Guardant Health Inc
GH
LISTED
NASDAQ
Guardant Health Announces Pricing of Upsized Public Offering of Common Stock
News Preview
Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of an upsized underwritten public offering of 3,333,333 shares of Guardant Health’s common stock at a public offering price of $90.00 per share (the “common stock offering”). The size of the common stock offering was increased...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: US6822831060
Onassis Holdings Corp.
ONSS
LISTED
OTC
Onassis Holdings Appoints Esq. Paz Itzhaki-Weinberger to Advisory Board to Oversee International Law and Trade
News Preview
NEW YORK, Nov. 5, 2025 /PRNewswire/ -- Onassis Holding Corp (OTC: ONSS) a US public company pioneering cellular rejuvenation and longevity biotechnology, is pleased to announce the appointment of Esq. Paz Itzhaki-Weinberger to its Advisory Board. Paz will lead the company's strategy on international law, trade, a...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
05.11.2025
ISIN: CA0717341071
Bausch Health Companies Inc
BHC
LISTED
TSX
Bausch Health's OraPharma Expands into Canada and Puerto Rico, Helping to Address Unmet Needs in Periodontal Disease
News Preview
Expansion improves access to treatment options within periodontal care and helps strengthen partnerships with dental professionals within these populations. LAVAL, QC / ACCESS Newswire / November 5, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global diversified pharmaceutical company, and OraPharma, its dental products business, toda...
Themefolio
Profiler
Peergroup
© EQS Newswire
05.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Continued strong execution on strategic priorities
News Preview
Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand; Just – Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerating growth on non-Sandoz / non-DOD business
Strong scientific advancements of co-developed asset pipeline: Expecting up to four mo......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Weiterhin konsequente Umsetzung strategischer Prioritäten
News Preview
Konzernumsatz von 535,1 Mio. € (-7,1 %); Discocery & Preclinical Development-Segment ("D&PD", -12,3 %) mit weiterhin zurückhaltender Nachfrage; Just – Evotec Biologics ("JEB", +11,3 %) übertrifft Erwartungen; weiter beschleunigtes Wachstum außerhalb der Kooperationen mit Sandoz und dem US-amerikanischen Verteidigungsministerium Depa......
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: DK0015998017
Bavarian Nordic A/S
BAVA
LISTED
CPH
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
News Preview
COPENHAGEN, Denmark, November 5, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4.92% of the shares and voting rights in Bavarian Nordic A/S as of October 30, 2025....
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: CH1335392721
Galderma Group AG
GALD
LISTED
XWSX
Galderma Receives U.S. FDA Approval for Restylane® Lyft™ for the Enhancement of the Chin Profile
News Preview
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Lyft with Lidocaine for augmentation of the chin region to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion.2 Restylane Lyft is a versat...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: FR0010331421
Innate Pharma SA
IPH
LISTED
EURONEXT
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the Company will hold a conference call on Thursday, November 13, 2025, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2025.
Participants during the call will be:
Jonathan Dickins...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: DK0062498333
Novo Nordisk A/S
NOVO B
LISTED
CPH
Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues
News Preview
Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US45256X1037
Immunitybio Inc
IBRX
LISTED
NASDAQ
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
News Preview
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced its financial results for the fiscal quarter and nine months ended September 30, 2025.
In the third quarter of 2025, ImmunityBio reported $31.8 million of product revenue, representing a 434% increase from $6.0 million in the third quarter of 2024. This growth refl...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Nov. 4, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: A...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
BAX Investors Have Opportunity to Lead Baxter International Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Nov. 4, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (N...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Nov. 4, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ:...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: VGG111961055
Biohaven Ltd.
BHVN
LISTED
NYSE
FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia
News Preview
The troriluzole clinical development program encompassed the first industry clinical trials to generate data showing therapeutic potential in patients with spinocerebellar ataxia (SCA), a rare genetic, inherited, life-threatening neurodegenerative disease with no treatment options....
Themefolio
Profiler
Peergroup
© ACCESSWIRE
05.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
News Preview
Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerating growth on non-Sandoz / non-DOD businessStrong scientific advancements of co-developed asset pipeline: Expecting u...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: SG9999014716
WAVE Life Sciences Ltd
WVE
LISTED
NASDAQ
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
News Preview
Presentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for the treatment of obesity designed to drive fat loss while preserving muscle mass with once or twice annual dosing...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: KYG4818G1010
Innovent Biologics Inc
1801
LISTED
HKSE
Multiple Research Results from Innovent's General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting
News Preview
SAN FRANCISCO and SUZHOU, China, Nov. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology a...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: KYG0405D1051
Angelalign Technology Inc
6699
LISTED
HKSE
Angelalign Technology Expands Partnerships with Dexis™, Shining 3D, and Panda Scanner in iOrtho Release 5.3
News Preview
SAN CLEMENTE, Calif., Nov. 4, 2025 /PRNewswire/ -- Angelalign Technology Inc. (6699.HK) ("Angel") today announced the expansion of its flexible iOrtho® platform to include direct integration with the Dexis, Shining 3D, and Panda scanner. This new integration further strengthens iOrtho's open platform, which alrea...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: KYG4672N1198
HUTCHMED (China) Ltd
13
LISTED
HKSE
HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the completion of patient enrollment of SAFFRON, a global Phase III study of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with epidermal growth fact...
Themefolio
Profiler
Peergroup
© Newsfile
05.11.2025
ISIN: CA62858B1085
MyndTec Inc.
MYTC
LISTED
CSE
MyndTec Inc. Completes Seventh Tranche of Non-Brokered Private Placement
News Preview
Mississauga, Ontario--(Newsfile Corp. - November 4, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed the seventh tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offeri...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US70805E1091
Pennant Group Inc
PNTG
LISTED
NASDAQ
Pennant Acquires Senior Living Communities in Idaho and Wisconsin
News Preview
EAGLE, Idaho, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announces two significant acquisitions that strengthen its presences in key markets....
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: CA24874B1085
dentalcorp Holdings Ltd.
DNTL
LISTED
TSX
Dentalcorp Announces Receipt of Interim Order and Update Regarding Proposed Acquisition by Investment Funds Affiliated with GTCR
News Preview
dentalcorp Holdings Ltd. (“Dentalcorp” or the “Company”) (TSX: DNTL), Canada’s largest and one of North America’s fastest growing networks of dental practices, today announced that the Supreme Court of British Columbia has granted Dentalcorp an interim order providing for the calling and holding of the special meeting of Dentalcorp securityholders...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US89422G1076
Travere Therapeutics Inc
TVTX
LISTED
NASDAQ
Travere Therapeutics to Participate at Upcoming Investor Conferences
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences:
Guggenheim's 2nd Annual Healthcare Innovation Conference
Presenting on Tuesday, November 11, 2025, at 9:00 a.m. ET
Stifel 2025 Healthcare Conference
Wednesday, November 12, 2025
TD Cowen Immunology &...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US6707031075
Nuvalent Inc
NUVL
LISTED
NASDAQ
Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer
News Preview
Encore pivotal efficacy and safety data from the ARROS-1 trial also to be presented during poster session
CAMBRIDGE, Mass., Nov. 4, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targe...
Themefolio
Profiler
Peergroup
© Newsfile
04.11.2025
ISIN: CA60256C2076
MindBio Therapeutics Corp.
MBIO
LISTED
CSE
CSE Bulletin: Consolidation - MindBio Therapeutics Corp. (MBIO)
News Preview
Toronto, Ontario--(Newsfile Corp. - Le 4 novembre/November 2025) - MindBio Therapeutics Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every four hundred (400) pre-consolidated common shares. As a result, the number of outstanding shares...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LNTH Deadline: LNTH Investors with Losses in Excess of $100K Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Nov. 4, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDA...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US2307701092
Cumberland Pharmaceuticals, Inc.
CPIX
LISTED
NASDAQ
CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH
News Preview
NASHVILLE, Tenn., Nov. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $8.3 million during the third quarter of 2025. Year-to-date revenues for the first...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: CA89788C1041
Trulieve Cannabis Corp
TRUL
LISTED
CSE
Trulieve Announces Notice of Redemption for All US$368 Million of its 8.0% Senior Secured Notes due 2026
News Preview
TALLAHASSEE, Fla., Nov. 4, 2025 /CNW/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced it has issued a notice of redemption for all of its outstanding 8.0% senior secured notes due 2026 (CUSIP: 89788CAD6...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: CA89788C1041
Trulieve Cannabis Corp
TRUL
LISTED
CSE
Trulieve Announces Notice of Redemption for All US$368 Million of its 8.0% Senior Secured Notes due 2026
News Preview
TALLAHASSEE, Fla., Nov. 4, 2025 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced it has issued a notice of redemption for all of its outstanding 8.0% senior secured notes due 2026 (CUSIP: 89...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US14149Y1082
Cardinal Health Inc
CAH
LISTED
NYSE
Cardinal Health Board of Directors Approves Quarterly Dividend
News Preview
DUBLIN, Ohio, Nov. 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on January 15, 2026 to shareholders of record at the close of business on Janu...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US00973Y1082
Akero Therapeutics Inc
AKRO
LISTED
NASDAQ
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
News Preview
PHILADELPHIA, Nov. 4, 2025 /PRNewswire/ -- Berger Montague PC advises shareholders of Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company and members of its Board of Directors for potential breaches of fiduciary duties and violations of the federal securities laws....
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US40131M1099
Guardant Health Inc
GH
LISTED
NASDAQ
Guardant Health Announces Proposed Public Offering of Common Stock
News Preview
Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the commencement of an underwritten public offering of $250.0 million of shares of Guardant Health’s common stock (the “common stock offering”). Guardant Health also intends to grant the underwriters a 30-day option to purchase up to an ad...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US40131M1099
Guardant Health Inc
GH
LISTED
NASDAQ
Guardant Health Announces Proposed $300.0 Million Offering of Convertible Senior Notes Due 2033
News Preview
Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $300.0 million aggregate principal amount of convertible senior notes due 2033 (the “notes”) in a private offering (the “convertible notes offering”) to persons reasonably believed to be qualified institutional buyer...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US87990A1060
Tenaya Therapeutics Inc
TNYA
LISTED
NASDAQ
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025
News Preview
Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK™-1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US74051N1028
Premier Inc
PINC
LISTED
NASDAQ
Premier Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Premier, Inc. - PINC
News Preview
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Premier, Inc. (NasdaqGS: PINC) to an affiliate of Patient Square Capital. Under the terms of the proposed transaction, shareholders of Premier will receive $28.25 in cash for each share of Pr...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US71742Q1067
Phibro Animal Health Corp
PAHC
LISTED
NASDAQ
Phibro Animal Health Corporation Declares Quarterly Dividend
News Preview
The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 17, 2025, to stockholders of record at the close of business on November 26, 2025.
About Phibro Animal Health Corporation
Phibro Animal Heal...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
ISIN: CH1243598427
Sandoz Group AG
SDZ
LISTED
XWSX
Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire Just-Evotec Biologics EU SAS in Toulouse
News Preview
Sandoz Group AG
/ Key word(s): Agreement
Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire Just-Evotec Biologics EU SAS in Toulouse 04.11.2025 / 22:05 CET/CEST
Acquisition will enable expansion of in-house development and manufacturing capabilities and provide Sandoz with own capabilities for the ......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments potentially over US$ 650 m plus royalties
News Preview
In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments potentially over US$ 650 m plus royalties on portfolio of up to 10 biosimilar molecules
Transaction showcases Evotec’s unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing techn......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über 650 Mio. US$ zuzüglich Umsatzbeteiligungen
News Preview
In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über 650 Mio. US$ zuzüglich Umsatzbeteiligungen an einem Portfolio von bis zu 10 Biosimilar-Molekülen
Die Transaktion unterstreicht Evotecs einzigartige Fähigkeiten Kunden durch ihre kontinuierliche Produktionsstechn......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
